Paclitaxel Mylan

Paclitaxel, the active ingredient in Paclitaxel Mylan, is a chemotherapy agent presented as a sterile powder for intravenous infusion use. It treats various solid tumours and is administered to adult oncology patients.

GNH USA supplies Paclitaxel Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Paclitaxel is a mitotic inhibitor that acts on the cell division cycle of solid tumours in several oncologic pathways and offers clinical benefits across multiple indications.

- Breast cancer: Improves the response to taxane based chemotherapy and increases overall survival in combination regimens for advanced disease. - Non‑small cell lung cancer: Provides tumour shrink  and disease control when used with carb ‑ cis or carboplatin regimens . - Ovarian cancer: Enhances progression‑free survival when combined with platinum based therapy . - Gastric and gastro‑intestinal tumours : Used as part of first line treatment in combination with flu‑  -  C   S  ​    ", -